CADL
Candel Therapeutics, Inc.
$9.48
-0.16 (-1.66%)
At close · Jul 16
Market Cap
$694.60M
Shares
73,270,239
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | CEO | $5,344,561 |
| Francesca Barone | Chief Scientific Officer | $1,561,536 |
| Charles Schoch | CFO | $1,470,817 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | CEO | $1,449,222 |
| Francesca Barone | Chief Scientific Officer | $726,222 |
| Seshu Tyagarajan | Chief Technical and Development Officer | $613,231 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | CEO | $1,484,759 |
| Francesca Barone | Chief Scientific Officer | $706,876 |
| Jason A. Amello | CFO | $692,025 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | CEO | $1,844,971 |
| Seshu Tyagarajan | Chief Technical and Development Officer | $916,020 |
| Francesca Barone | Chief Scientific Officer | $908,302 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | CEO | $956,800 |
| Estuardo Aguilar-Cordova | CEO | $526,386 |
| John Canepa | CFO | $449,123 |
| Francesca Barone | Chief Scientific Officer | $364,797 |
| Seshu Tyagarajan | Chief Technical and Development Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | CEO | $2,626,511 |
| John Canepa | CFO | $1,319,316 |
| Estuardo Aguilar-Cordova | CEO | $740,153 |